Pelthos Therapeutics Inc.

Pelthos Therapeutics Inc. is a biopharmaceutical company that develops and commercializes therapeutic products for patients with unmet treatment needs. Its offerings include ZELSUVMI for molluscum contagiosum in adults and children aged 1 year and older; XEPI (ozenoxacin) cream, a quinolone antimicrobial for impetigo caused by Staphylococcus aureus or Streptococcus pyogenes in patients aged 2 months and older; and XEGLYZE, a pediculicide for topical treatment of head lice infestation in patients aged 6 months and older. The company also provides NITRICIL, a proprietary nitric oxide-based technology platform. Formerly known as Channel Therapeutics Corporation, it changed its name to Pelthos Therapeutics Inc. in July 2025. Founded in 2002, the company is based in Durham, North Carolina.